University of New Mexico Cancer Center Support

服务于一个巨大的美丽的地理区域，具有丰富的多元文化和多民族多样性，巨大的科学 机会，挑战健康和社会经济差距，新墨西哥州癌症中心及其 联盟机构- Lovelace呼吸研究所，洛斯阿拉莫斯国家实验室和桑迪亚国家实验室 实验室-是独特的准备作出重大进展，在癌症研究和服务于我们的社区， 我们的国家作为500英里半径内唯一的NCI癌症中心，UNM癌症中心的特殊性 中心包括：它所服务的多种族和多文化人口-主要是西班牙裔/拉丁裔，美洲印第安人， 和非西班牙裔白色-与他们的癌症发病率，死亡率和差异的显着不同的模式; 整合工程、生物技术、纳米技术、放射性同位素、药物发现、 成像和高性能计算纳入其研究计划和共享资源; 它建立了全州范围的外展网络，用于提供癌症护理， 教育和参与性研究，并为社区肿瘤学家参与UNM癌症中心临床 审判自2005年上一次NCI P30 CCSG审查以来，该中心的年度同行评审研究经费已 总成本增加40%，超过4680万美元，而NCI的年度资金增加30%，超过1380万美元 百万美元。该中心117个成员之间的方案内和方案间合作， 显著增加，在4个研究项目中的每一个项目中的范围从20-48%：癌症人口科学， 癌症生物学和生物技术，血液系统恶性肿瘤和妇女癌症。癌症中心成员 领导9个NIH资助的高通量靶点筛选和分子发现路线图中心之一 （U 54 MH 084690），10个NIH资助的国家系统生物学中心之一（P50 GM 085273），4个NSF/NCI之一 集成纳米科学和微系统培训中心（DGE 0504276），20个LLS专业中心之一 白血病研究（LLS SCOR 7388-06）和跨学科HPV预防中心（NIH U19 AI 084081）。到 确保所有新墨西哥人都能获得出色的癌症诊断和治疗，UNM癌症中心 新的206，432平方米英尺，9000万美元，2009年8月，癌症治疗和临床研究设施， 作为UNM全州癌症护理网络的中心。在与西门子的合作中，这一新设施包括 一个放射性同位素生产实验室和实验放射性药物学，这将加速该中心的研究 程序.从2008年1月7日至2009年1月7日，在保持其使命的服务不足和无保险，新墨西哥大学癌症中心 在该中心治疗的2640名新诊断患者中，有443名（17%）参加了治疗性临床试验; 这些患者是西班牙裔或美洲印第安人。社区附属机构为UNM增加了另外101名患者 治疗试验此外，该中心在此期间有845项不干预协议。整体 UNM癌症中心的目标是：1）在我们的实验室，诊所和医院进行杰出的跨学科研究。 和多种族和多文化的社区，建立在我们独特的科学和区域优势; 2）减少 通过发现遗传、环境、社会和行为因素， 导致了美国西南部人民不同的癌症模式和癌症差异; 3） 将我们的科学发现转化为新的诊断、筛查、预防和治疗工具以及临床试验; 4）为所有新墨西哥人提供优秀的癌症治疗和临床试验。

Serving a vast geographic region of great beauty, with rich multicultural and multiethnic diversity, tremendous scientific opportunity, and challenging health and socioeconomic disparities, the University of New Mexico Cancer Center and its consortium institutions - Lovelace Respiratory Research Institute, Los Alamos National Laboratory, and Sandia National Laboratories - are uniquely poised to make significant advances in cancer research and to serve our communities and our nation. As the only NCI Cancer Center within a 500 mile radius, the special characteristics of the UNM Cancer Center include: the multiethnic and multicultural populations that it serves - primarily Hispanic/Latino, American Indian, and non-Hispanic White - with their strikingly different patterns of cancer incidence, mortality, and disparity; the integration of regional scientific strengths in engineering, biotechnology, nanotechnology, radioisotopes, drug discovery, imaging, and high performance computing into its Research Programs and Shared Resources; and the extensive statewide outreach networks it has built for the delivery of cancer care, for culturally appropriate community-based education and participatory research, and for the participation of community oncologists in UNM Cancer Center clinical trials. Since the previous NCI P30 CCSG review in 2005, the Center's annual peer-reviewed research funding has increased 40% to over $46.8 million dollars in total costs, while annual funding from NCI increased 30% to over $13.8 million dollars. Intra-programmatic and inter-programmatic collaborations among the 117 members of the Center have increased markedly and range from 20-48% in each of the 4 Research Programs: Cancer Population Sciences, Cancer Biology and Biotechnology, Hematologic Malignancies, and Women's Cancers. Cancer Center members lead one of 9 NIH-funded Roadmap Centers for High Throughput Target Screening and Molecular Discovery {U54MH084690), one of 10 NIH-funded National Centers for Systems Biology (P50GM085273), one of 4 NSF/NCI Centers for Integrative Nanoscience and Microsystems Training (DGE0504276), one of 20 LLS Specialized Centers ol Leukemia Research (LLS SCOR 7388-06), and an Interdisciplinary HPV Prevention Center (NIH U19AI084081). To assure that all New Mexicans have access to outstanding cancer diagnosis and treatment, the UNM Cancer Center opened its new 206,432 sq. ft., $90 million, Cancer Treatment and Clinical Research Facility in August 2009 which serves as the hub of the UNM Statewide Cancer Care Network. In collaboration with Siemens, this new facility contains a radioisotope production laboratory and experimental radiopharmacy, which will accelerate the Center's research programs. From 7/1/08-7/1/09, while maintaining its mission to the underserved and uninsured, the UNM Cancer Center accrued 443 (17%) of the 2640 newly diagnosed patients treated at the Center to therapeutic clinical trials; 51% of these patients were Hispanic or American Indian. Community affiliates accrued another 101 patients to UNM therapeutic trials. In addition, the Center had 845 accruals to non-intervention protocols in this time period. The overall goals of the UNM Cancer Center are to: 1) conduct outstanding transdisciplinary research in our laboratories, clinics and multiethnic and multicultural communities that builds upon our unique scientific and regional strengths; 2) reduce the burden of cancer incidence and mortality by discovering the genetic, environmental, social, and behavioral factors that contribute to the distinct cancer patterns and cancer disparities in the peoples of the American Southwest; 3) translate our scientific discoveries to novel diagnostic, screening, prevention, and therapeutic tools and clinical trials; and 4) provide access to outstanding cancer treatment and clinical trials for all New Mexicans.